Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.
Dhiren KumarIdris YakubuFrough SafaviMarlon LevyIrfan MoinuddinPamela KimballLayla KamalAnne KingDavis MasseyPhilip HalloranGaurav GuptaPublished in: Kidney360 (2020)
In this early experience, we report a lack of efficacy and toxicity with the use of TCZ for caAbMR. Prospective clinical trials are needed to clarify the role of IL-6 blockade and the possibility of increased incidence of infections in patients with caAbMR who are treated with TCZ.